Effects of KF19514, a phosphodiesterase 4 and 1 inhibitor, on bronchial inflammation and remodeling in a murine model of chronic asthma

Allergology International

Volumn 58, Issue 2, 2009, Pages 267-275

  Kita, Toshiyuki ^a   Fujimura, Masaki ^a   Myou, Shigeharu ^a   Watanabe, Kazuyoshi ^a   Waseda, Yuko ^a   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Airway hyperresponsiveness; Airway remodeling; Asthma; Murine model; PDE inhibitor

Indexed keywords

5 PHENYL 3 (3 PYRIDIL)METHYL 3H IMIDAZO[4,5 C] [1,8]NAPHTHYRIDIN 4(5H)ONE; ACETYLCHOLINE; COLLAGEN; HYDROXYPROLINE; KF 19514; OVALBUMIN; PHOSPHODIESTERASE I INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; BRONCHITIS; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; BRONCHUS REACTIVITY; CHRONIC INFLAMMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EOSINOPHIL; FEMALE; INFLAMMATORY CELL; LAMINA PROPRIA; LONG TERM EXPOSURE; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION;

ACETYLCHOLINE; ANIMALS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTION; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 1; FEMALE; HYDROXYPROLINE; INFLAMMATION; LUNG; MICE; MICE, INBRED BALB C; MUCOUS MEMBRANE; NAPHTHYRIDINES; OVALBUMIN; PHOSPHODIESTERASE 4 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; PULMONARY EOSINOPHILIA; RESPIRATORY MUCOSA; SPECIFIC PATHOGEN-FREE ORGANISMS; TRACHEA; VACCINATION;

EID: 67651163869     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.08-OA-0053     Document Type: Article

References (47)

1. Roche WR, Beasley R, Williams JH, Holgate ST. Sub-epithelial fibrosis in the bronchi of asthmatics. Lancet 1989;1:520-4.
2. Wilson JW, Li X. The measurement of reticular basement membrane and submucosal collagen in the asthmatic airway. Clin Exp Allergy 1997;27:363-71.
3. Laitinen A, Altraja A, Kampe M, Linden M, Virtanen I, Laitinen LA. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am J Respir Crit Care Med 1997; 156:951-8.
4. Brewster CEP, Howarth PH, Djukanovic R, Wilson J, Holgate ST, Roche WR. Myofibroblast and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1990;3:507-11.
5. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998;339:1194-200.
6. Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A, Olivieri D. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 1997; 111:852-7.
7. Selroos O, Pietinalho A, Lofroos A, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995; 108:1228-34.
8. Chetta A, Foresi A, Del Donno M et al. Bronchial responsiveness to distilled water and methacholine and its relationship to inflammation and remodeling of the airways in asthma. Am J Respir Crit Care Med 1996;153:910-7.
9. Niimi A, Matsumoto H, Amitani R et al. Airway wall thickess in asthma assessed by computed tomography: relation to clinical indices. Am J Respir Crit Care Med 2000; 162:1518-23.
10. Sont JK, Willems LN, Bel EH, van Krieken JH, Vendenbroucke JP, Sterk PJ and the AMPUL Study Group. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long term treatment. Am J Respir Crit Care Med 1999; 159:1043-51.
11. Housley MD, Adams RD. PDE4 cAMP phosphodiesterases: modulate enzymes that orchestrate signaling cross-talk, desensitization and compartmentalizatuion. Biochem J 2003;370:1-18.
12. Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C. Cyclic AMP specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 2003; 278:5463-96.
13. Manabe H, Akuta K, Sejimo H et al. Anti-inflammatory and bronchodilator properties of KF19514, a phosphodiesterase 4 and 1 inhibitor. Eur J Pharmacol 1997;332:97-107.
14. Fujimura M, Kita T, Myou S, Tachibana H, Matsuda T. Bronchoprotective effects of KF-19514 and cilostazol in guinea pigs in vivo. Eur J Pharmacol 1997;327:57-63.
15. Myou S, Fujimura M, Kurashima K, Tachibana H, Hirose T, Nakao S. Effect of aerosolized administration of KF19514, a phosphodiesterase 4 inhibitor, on bronchial hyperresponsiveness and airway inflammation induced by antigen inhalation in guinea-pigs. Clin Exp Allergy 2000; 30:713-8.
16. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;297:267-79.
17. Kumar RK, Herbert C, Thomas PS et al. Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther 2003;307:349-55.
18. Temelkovski J, Hogan SP, Shepherd DP, Foster PS, Kumar PK. An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolized allergen. Thorax 1998;53:849-56.
19. Konzett H, Rossler R. Versuchanordnungzu untersuchungen an der bronchialmusukulatur. Arch Exp Pathol Pharmak 1940;195:71-4 (in German).
20. Sogur N, Fujimura M, Mizuhashi K, Saito M, Xiu QY, Matsuda T. Involvement of thromboxane A2 in propranolol-induced bronchoconstriction after allergic bronchoconstriction in guinea pigs. Am J Respir Crit Care Med 1994;149:1488-93.
21. Fujimura M. [Inhibitory effects of steroids on slow reacting substance of anaphylaxis (SRS-A) mediated bronchoconstriction in the guinea pig in vivo]. Jpn J Allergol 1983;32:365-75 (in Japanese).
22. Sullivan P, Stephens D, Ansari T, Costello J, Jeffery P. Variation in the measurements of basement membrane thickness and inflammatory cell number in bronchial biopsies. Eur Respir J 1998;12:811-5.
23. Huszar G, Maiocco J, Naftolin F. Monitoring of collagen and collagen fragments in chromatography of protein mixtures. Anal Biochem 1980;105:424-9.
24. Stewart AG, Tomlinson PR, Wilson J. Airway wall remodeling in asthma; a novel target for the development of anti-asthma drugs. Trends Pharmacol Sci 1995;14:275-9.
25. Anderson GP, Coyle AJ. Th2 and 'Th2-like' cells in allergy and asthma; pharmacological perspectives. Trends Pharmacol Sci 1994; 15:324-32.
26. Sahabuddin S, Ponath P, Schleimer RP. Migration of eosinophils across endoepithelial cell monolayers: interactions among IL-5, endothelial-activating cytokines, and C-C chemokines. J Immunol 2000;164:3847-54.
27. Campbell EM, Charo IF, Kunkel SL et al. Monocyte chemoattractant protein-1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2-/- mice: the role of mast cells. J Immunol 1999;163: 2160-7.
28. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001;108:671-80.
29. Manabe H, Ohnuma K, Ichimura M, Kawakita T, Suzuki F, Ohmori K. Pharmacological properties of a new bronchodilator, KF19514. Jpn J Pharmacol 1995;67 (Suppl): S24.
30. Howell RE, Sickels BD, Woeppel SL. Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs. J Pharmacol Exp Ther 1993;264:609-15.
31. Lagente V, Moodley I, Perrin S, Mottin G, Junien JL. Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung. Eur J Pharmacol 1994; 255:253-6.
32. Underwood DC, Osborn RR, Nova LB et al. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J Pharmacol Exp Ther 1993;266:306-13.
33. Lagente V, Pruniaux MP, Junien JL, Moodley I. Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors. Am J Respir Crit Care Med 1995; 151:1720-4.
34. Torphy TJ, Undem BJ, Cieslenski LB, Luttmann MA, Reeves ML, Hay DWP. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J Pharmacol Exp Ther 1993; 265:1213-23.
35. Boer J, Philpott AJ, Amsterdam GM, Shahid M, Zaagsma J, Nicholson CD. Human bronchial cyclic nucleotide phosphodiesterase isozymes: Biochemical and pharmacological analysis using selective inhibitors. Br J Pharmacol 1992;106:1028-34.
36. Teixeria MM, Rossi AG, Williams TJ, Hellewell PG. Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig. Br J Pharmacol 1994;112:332-40.
37. Nicholson CD, Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isozymes-their potential utility in the therapy of asthma. Pul Pharmacol 1994;7:1-17.
38. Barns PJ. Cyclic nucleotides and phosphodiesterases and airway function. Eur Respir J 1995;8:457-62.
39. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 57:351-70.
40. Weston MC, Anderson N, Peachell PT. Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function. Br J Pharmacol 1997;121:287-95.
41. Verghese MW, McConnell RT, Strickland AB et al. Differential regulation of human monocyte-derived TNF and IL-1 by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Ther 1995;272:1313-20.
42. Souness JE, Houghton C, Sardar N, Withnall MT. Suppression of anti-CD3-induced interleukin-4 and interleukin-5 release from splenocytes of Mesocestoides corti-infected BALB/c mice by phosphodiesterase 4 inhibitors. Biochem Pharmacol 1999; 58:991-9.
43. Corbel M, Germain N, Lanchou J et al. The selective phosphodiesterase 4 inhibitor RP 73-401 reduced matrix metalloproteinase 9 activity and transforming growth factor- release during lung injury in mice: the role of the balance between tumor necrosis factor- and interleukin-10. J Pharmacol Exp Ther 2002;301:258-65.
44. Moreno RH, Hogg JC, Pare PD. Mechanics in airway narrowing. Am Rev Respir Dis 1986;133:1171-80.
45. Rybalkin SD, Bornfeldt KE, Sonnenburg WK et al. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest 1997;100:2611-21.
46. Rybalkin SD, Rybalkina I, Beavo JA, Bornfeldt KE. Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res 2002;90: 151-7.
47. Giembycz MA. Life after PDE4: overcoming adverse events with dual-specifity phosphodiesterase inhibitors. Curr Opin Pharmacol 2005;5:238-44.